文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

高流量与文丘里面罩氧疗预防低氧血症患者拔管后再插管:多中心随机临床试验

High-Flow Versus VenturiMask Oxygen Therapy to Prevent Reintubation in Hypoxemic Patients after Extubation: A Multicenter Randomized Clinical Trial.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01
一句话结论拔管后PaO2:FiO2≤300 mmHg的低氧血症患者,高流量氧疗与文丘里面罩的72小时再插管率无显著差异,但高流量氧疗减少补救无创通气需求。

该多中心随机试验纳入494例拔管后PaO2:FiO2≤300 mmHg的低氧血症患者,随机接受高流量氧疗或文丘里面罩氧疗,文丘里面罩组不允许使用高流量氧疗,再插管前可应用补救无创通气。主要终点为72小时内按预定标准再插管率,经独立裁决委员会事后验证(n=492)。高流量组32例(13%)与文丘里面罩组27例(11%)在72小时需再插管(未校正OR 1.26,95%CI 0.70-2.26;P=0.49)。28天再插管率分别为21%和23%(校正HR 0.89,95%CI 0.60-1.31;P=0.55)。补救无创通气需求高流量组显著更低:72小时8% vs 17%(校正HR 0.39,95%CI 0.22-0.71;P=0.002),28天12% vs 21%(校正HR 0.52,95%CI 0.32-0.83;P=0.007)。

要点

  • 拔管后PaO2:FiO2≤300 mmHg患者,高流量氧疗与文丘里面罩的72小时再插管率无显著差异(13% vs 11%,未校正OR 1.26,95%CI 0.70-2.26;P=0.49)。
  • 28天再插管率两组亦无显著差异:高流量组21% vs 文丘里面罩组23%(校正HR 0.89,95%CI 0.60-1.31;P=0.55)。
  • 高流量氧疗显著降低72小时补救无创通气需求:8% vs 17%(校正HR 0.39,95%CI 0.22-0.71;P=0.002)。
  • 28天补救无创通气需求高流量组仍显著更低:12% vs 21%(校正HR 0.52,95%CI 0.32-0.83;P=0.007)。
  • 文丘里面罩组不允许使用高流量氧疗,再插管前可应用补救无创通气。

适用人群与场景

  • 拔管后PaO2:FiO2≤300 mmHg的低氧血症患者,多中心随机试验纳入494例,主要分析n=492。

诊断标准与关键阈值

  • 再插管按预定标准判定,并由独立裁决委员会事后验证。

处置流程与药物剂量

  • 高流量氧疗组接受高流量氧疗,文丘里面罩组接受文丘里面罩氧疗,文丘里面罩组不允许使用高流量氧疗。
  • 再插管前可应用补救无创通气,按预定标准判定。

研究设计与关键结果

  • 多中心随机临床试验,494例拔管后PaO2:FiO2≤300 mmHg患者随机接受高流量氧疗或文丘里面罩氧疗,主要终点72小时再插管率经独立裁决委员会验证(n=492)。
  • 72小时再插管:高流量组32例(13%)vs 文丘里面罩组27例(11%),未校正OR 1.26(95%CI 0.70-2.26),P=0.49。
  • 28天再插管率:高流量组21% vs 文丘里面罩组23%,校正HR 0.89(95%CI 0.60-1.31),P=0.55。
  • 72小时补救无创通气需求:高流量组8% vs 文丘里面罩组17%,校正HR 0.39(95%CI 0.22-0.71),P=0.002。
  • 28天补救无创通气需求:高流量组12% vs 文丘里面罩组21%,校正HR 0.52(95%CI 0.32-0.83),P=0.007。

证据类型、等级与局限

  • 证据类型:多中心随机临床试验(RCT)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于拔管后PaO2:FiO2≤300 mmHg的低氧血症患者,高流量氧疗与文丘里面罩在再插管率上无显著差异,但高流量氧疗可减少补救无创通气的使用。

指南或共识出处

  • 临床试验注册号:NCT02107183(www.clinicaltrials.gov)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

Rationale: When compared with VenturiMask after extubation, high-flow nasal oxygen provides physiological advantages. Objectives: To establish whether high-flow oxygen prevents endotracheal reintubation in hypoxemic patients after extubation, compared with VenturiMask. Methods: In this multicenter randomized trial, 494 patients exhibiting PaO2:FiO2 ratio ⩽ 300 mm Hg after extubation were randomly assigned to receive high-flow or VenturiMask oxygen, with the possibility to apply rescue noninvasive ventilation before reintubation. High-flow use in the VenturiMask group was not permitted. Measurements and Main Results: The primary outcome was the rate of reintubation within 72 hours according to predefined criteria, which were validated a posteriori by an independent adjudication committee. Main secondary outcomes included reintubation rate at 28 days and the need for rescue noninvasive ventilation according to predefined criteria. After intubation criteria validation (n = 492 patients), 32 patients (13%) in the high-flow group and 27 patients (11%) in the VenturiMask group required reintubation at 72 hours (unadjusted odds ratio, 1.26 [95% confidence interval (CI), 0.70-2.26]; P = 0.49). At 28 days, the rate of reintubation was 21% in the high-flow group and 23% in the VenturiMask group (adjusted hazard ratio, 0.89 [95% CI, 0.60-1.31]; P = 0.55). The need for rescue noninvasive ventilation was significantly lower in the high-flow group than in the VenturiMask group: at 72 hours, 8% versus 17% (adjusted hazard ratio, 0.39 [95% CI, 0.22-0.71]; P = 0.002) and at 28 days, 12% versus 21% (adjusted hazard ratio, 0.52 [95% CI, 0.32-0.83]; P = 0.007). Conclusions: Reintubation rate did not significantly differ between patients treated with VenturiMask or high-flow oxygen after extubation. High-flow oxygen yielded less frequent use of rescue noninvasive ventilation. Clinical trial registered with www.clinicaltrials.gov (NCT02107183).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

参考来源

  1. Maggiore SM, Jaber S, Grieco DL, et al. High-Flow Versus VenturiMask Oxygen Therapy to Prevent Reintubation in Hypoxemic Patients after Extubation: A Multicenter Randomized Clinical Trial. Am J Respir Crit Care Med. 2022. PMID: 35849787. doi:10.1164/rccm.202201-0065OC

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。